ライフサイエンスコーパス: GPCMV

1 GPCMV DNA levels in the placenta were reduced from 3.54

2 GPCMV endothelial cell infection established either a fu

3 GPCMV endothelial cell infection requires the viral pent

4 GPCMV endothelial cells were lytically (EndoC) or persis

5 GPCMV proved to be sensitive to BDCRB (50% inhibitory co

6 GPCMV-seronegative guinea pigs received two subcutaneous

7 GPCMV-specific ELISA and interferon-gamma ELISpot respon

8 Deletion of a GPCMV genome-encoded PKR inhibitor results in a highly a

9 (and its attendant rescuant), generated on a GPCMV bacterial artificial chromosome construct, confirm

10 ious single-cycle (DISC) vaccine strategy, a GPCMV mutant virus was used that lacked the ability to e

11 the guinea pigs with salivary gland-adapted GPCMV.

12 ate (cHPMPC; 35 mg/kg) or placebo 24 h after GPCMV infection.

13 tion of epithelial cells and trophoblasts by GPCMV requires the viral glycoprotein pentamer complex (

14 ea pigs were inoculated with guinea pig CMV (GPCMV) during the late second/early third trimester of g

15 (VRPs) expressing GP83, the guinea pig CMV (GPCMV) homolog of the human CMV pp65 phosphoprotein.

16 evaluated for protection against congenital GPCMV infection.

17 or WT-GPCMV significantly reduced congenital GPCMV transmission compared to placebo (protective effic

18 ity and plaquing efficiency of cotransfected GPCMV viral DNA was enhanced by GP82.

19 train based on a guinea pig cytomegalovirus (GPCMV) capsid mutant was evaluated.

20 Guinea pig cytomegalovirus (GPCMV) encodes a glycoprotein pentamer complex (PC) for

21 e guinea pig and guinea pig cytomegalovirus (GPCMV) encoding functional HCMV homolog viral glycoprote

22 s expressing the guinea pig cytomegalovirus (GPCMV) homologs of the glycoprotein B (gB) and UL83 prot

23 nes encoding the guinea pig cytomegalovirus (GPCMV) homologs of the upper and lower matrix proteins o

24 ainst congenital guinea pig cytomegalovirus (GPCMV) infection was developed, characterized, and teste

25 ainst congenital guinea pig cytomegalovirus (GPCMV) infection.

26 B vaccine in the guinea pig cytomegalovirus (GPCMV) model of congenital infection.

27 s study used the guinea pig cytomegalovirus (GPCMV) model to examine replication-deficient whole-viru

28 valuated using a guinea pig cytomegalovirus (GPCMV) model.

29 ome structure of guinea pig cytomegalovirus (GPCMV) provides a useful model for the study of herpesvi

30 Guinea pig cytomegalovirus (GPCMV) provides a valuable model for congenital cytomega

31 CMV but requires guinea pig cytomegalovirus (GPCMV).

32 species-specific guinea pig cytomegalovirus (GPCMV).

33 species-specific guinea pig cytomegalovirus (GPCMV).

34 A disabled infectious single-cycle (DISC) GPCMV vaccine strain induced an antibody immune response

35 expression of PDGFRA in EndoC cells enabled GPCMV(PC(-)) infection via direct cell entry independent

36 rs (PECAM1, vWF, and FLI1) and evaluated for GPCMV infection.

37 d disease but have been poorly evaluated for GPCMV.

38 The PC is necessary for GPCMV epithelial cell/trophoblast tropism and congenital

39 As with human cytomegalovirus (HCMV), GPCMV uses a specific cell receptor (PDGFRA) for fibrobl

40 Efficacy was evaluated by immunizing GPCMV-naive guinea pigs twice with either 10(5) or 10(6)

41 In GPCMV challenge studies, vaccinated animals had varying

42 nicity by repair of a frameshift mutation in GPCMV gene GP129 using this approach provides a valuable

43 es and CD4(+) and CD8(+) T cell responses in GPCMV-seronegative female guinea pigs.

44 A GP83 null deletion mutant GPCMV (GP83dPC+) generated in the backdrop of glycoprote

45 up but significantly decreased the amount of GPCMV in tissues.

46 The translational impact of GPCMV research is potentially reduced if the virus does

47 (50 microM) had no effect on the quantity of GPCMV genomic DNA that was formed in infected cells.

48 as significantly lower, and reduced rates of GPCMV transmission were noted, for dams immunized with g

49 Salivary gland (SG)-passaged stocks of GPCMV are pathogenic, while tissue culture (TC) passage

50 rotection against a novel clinical strain of GPCMV (TAMYC), despite 100% identity in GP83 protein seq

51 rotection against a novel clinical strain of GPCMV.

52 on pup mortality or vertical transmission of GPCMV.

53 enged with 1 x 10(4) plaque-forming units of GPCMV in the third trimester.

54 ing, we investigated the effects of BDCRB on GPCMV.

55 Recombinant GPCMV with a targeted deletion of gp145 (designated Delt

56 owever, a dose of BDCRB sufficient to reduce GPCMV titers by 3 logs (50 microM) had no effect on the

57 P-HA) were bred for pregnancy and subsequent GPCMV challenge during the early third trimester.

58 safety, immunogenicity, and efficacy in the GPCMV model.

59 srupts GP129, which encodes a subunit of the GPCMV pentameric complex (PC) believed to govern viral e

60 Treatment of the GPCMV-infected pregnant dam with 1 dose of cHPMPC improv

61 Using the GPCMV model of congenital infection, this study demonstr

62 tivation function of GP82 was not limited to GPCMV, but was also observed for a heterologous virus, h

63 e challenged during pregnancy with wild-type GPCMV (10(5) PFU).

64 fered saline, GP51-DD, GP52-DD, or wild-type GPCMV (WT-GPCMV).

65 viremia and fetal infection after wild-type GPCMV challenge during pregnancy.

66 cs of the GP83 mutant (vAM409) and wild-type GPCMV indicated that GP83 protein is not required for vi

67 d by comparing the pathogenesis of wild-type GPCMV, vAM409, and a control virus, vAM403, in guinea pi

68 nd challenged during pregnancy with virulent GPCMV, DNAemia was detected in all sham-immunized contro

69 Pregnant dams were challenged with GPCMV subcutaneously during the 3rd trimester.

70 ike those of pups in the control group, with GPCMV transmission being approximately 80%.

71 ne, GP51-DD, GP52-DD, or wild-type GPCMV (WT-GPCMV).

72 vaccination was noted in 10/10 (100%) of WT-GPCMV-immunized animals but in only 10/28 animals (36%)

73 Immunization with GP52-DD, GP51-DD, or WT-GPCMV significantly reduced congenital GPCMV transmissio

74 absent in dams immunized with GP51-DD or WT-GPCMV.

75 cient GP52-DD vaccines were comparable to WT-GPCMV in immunogenicity and protective efficacy.IMPORTAN